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tRNA modifications are a pivotal aspect of biology observed across all domains of life.  
These modifications rely on the presence of enzymes to induce the addition or deletion of groups 
on a tRNA.  One of these enzymes is Trm10, which exists as three different homologs within the 
human body: denoted TRMT10A, TRMT10B, and TRMT10C.  These proteins methylate at the 
N-1 position of nucleic acids at the 9th position of the tRNA, such that TRMT10A methylates a 
guanine to make N-1 methylguanosine (at the 9th position is denoted m1G9), TRMT10B 
methylates an adenine to make N-1 methyladenosine (at the 9th position is denoted m1A9), and 
TRMT10C performs both m1G9 and m
1A9.  In recent years, studies have demonstrated the 
importance of the SpoU Trm-D core of the protein (SPOUT core) in relation to this activity, but 
relatively little is known about the significant number of upstream and downstream residues on 
the protein, which comprise its N and C-terminal domains.  These protein domains have little 
sequence conservation across species and domains of life, and their role in Trm10 activity 
remains unknown. 
This project seeks to elucidate whether the presence of different upstream and 
downstream sequences would alter the activity of the SPOUT core of each type of TRMT10 by 
creating chimeric proteins where sequences from TRMT10A and B are mixed together.  This 
way, terminal domains of TRMT10A are connected to a TRMT10B core and vice versa.  Upon 
completion of this work, I have demonstrated that a construct with a TRMT10A core and 
TRMT10B upstream and downstream fragments (denoted BAB) does not show any activity, 
while all other TRMT10A core chimera retain m1G9 activity.  On the other hand, no TRMT10B 
chimeric proteins displayed any activity in the assays I performed.  These results suggest the 
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possibility that there is a role played in having at least one of the TRMT10A terminal domains 






























It is well established that the flow of genetic information within organisms follows the 
central dogma of biology, with that being that genetic information DNA is transcribed into 
mRNA using RNA polymerases, which is then subsequently translated into protein via 
ribosomes with the help of tRNA. This simplified view overlooks multiple substages to this 
complex process, including regulatory steps.  In all domains of life, this regulation exists through 
multiple different mechanisms, including through histone acetylation and deacetylation, mRNA 
alternative splicing, and tRNA modification, which is the most commonly modified RNA type 
(Phizicky and Hopper, 2010).  These modification mechanisms along with their respective 
enzymes allow for the up and down regulation of translation, as well as alteration of tRNA 
activity as a whole (Jackman and Alfonzo, 2013). The enzymatic reactions which regulate tRNA 
activity include methylations, aminations, deaminations, thiolations, and many more complicated 
chemical changes (Jackman and Alfonzo, 2013).  Many of these regulatory processes and their 
respective enzymes are conserved throughout most species, which suggests they may hold 
important roles in genetic information transfer (Swinehart et. al. 2013). With this being said, a 
major issue today in studying tRNA modification exists in the fact that the characterization of a 
post-transcriptional modification’s effect on tRNA function is very complex, as it is quite 
common that multiple modifications work in conjunction with one another as well as the 
surrounding environment to alter the activity of the tRNA (Jackman and Alfonzo, 2013).  Along 
with this, many unanswered questions exist for many of the tRNA modification enzymes where 
the molecular role of large portions of their amino acid sequences remain unknown, and Trm10 
is no exception. 
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The tRNA methyltransferase 10, or Trm10, is one of the enzymes that methylates at the 
ninth position on a tRNA, and while its role in organisms at a large scale is unknown, it is still 
known to be important due to Trm10 being highly conserved across a plethora of Archaea and 
Eukarya, with most of the enzymes studied initially performing m1G9 activity (methylation of the 
guanosine at the 9th position), similar to the original enzyme in this family that was identified in 
the yeast Saccharomyces cerevisiae (Jackman et. Al., 2003; Swinehart et. Al., 2013; Van Laer et. 
Al., 2016).  Some organisms encode more than one type of Trm10, with humans being one of 
those organisms along with other metazoa.  There are 3 forms of human Trm10 homologs, which 
were named A, B and C (denoted TRMT10A, TRMT10B, and TRMT10C) (Vilardo et. al., 2020; 
Howell et. al. 2019).  TRMT10A and TRMT10B are found in the cytosol, while TRMT10C is 
strictly a mitochondrial enzyme (Vilardo et. al., 2020; Howell et. al, 2019). It has been 
determined that TRMT10A performs m1G9 activity, while TRMT10B performs the m
1A9 
activity, and lastly TRMT10C performs both m1G9 and m
1A9 activity within the mitochondria 
(Howell et. al., 2019; Vilardo et. Al., 2012).  With this being said, tRNAAsp is the only known 
substrate for TRMT10B activity and it holds an adenine in the 9th position of the tRNA, while 
TRMT10A is less specific, and is capable of catalyzing m1G9 activity with many different tRNA 
substrates in vitro and in vivo (Howell et. al., 2019). It has recently been discovered that a lack of 
TRMT10A functionality in humans leads to microcephaly and metabolic defects, proving the 
essential nature of this enzyme in the body (Igoillo-Esteve et. al, 2013; Gillis et. Al., 2014). This 
also points to the independent nature of these proteins, as even in the presence of active 
TRMT10B or C (because the genes are unmutated in human patients who carry mutations in 
TRMT10A) these genetic diseases persist without TRMT10A functionality.  While it is well 
established that the main active site for Trm10 tRNA modifications is the S-adenosyl methionine 
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(SAM) binding domain, there exists large N- and C-terminal domains on either side of the SAM 
binding domain that are largely unknown in regards to function (Krishnamohan and Jackman, 
2017). In fact, studies have shown that the presence of the SPOUT core (SpoU-TrmD core) 
alone, which houses the SAM binding domain, is sufficient for each enzymes respective activity, 
but the presence and sequence conservation of parts of these seemingly extraneous sequences 
suggest they may be somewhat important.  This SPOUT core shows high conservancy due to it 
housing the SAM binding domain.  Being that these segments also compose a large portion of 
the protein by number of amino acids, it is important to determine their role, if any exists in 
regards to tRNA modification. 
To better understand the function and roles that these N- and C-terminal segments play in 
TRMT10 activity, the DNA sequences corresponding to the TRMT10A and TRMT10B proteins 
were analyzed using a multi-species sequence alignment so that the conserved SPOUT sequences 
were not disrupted, and the sequences could be segmented without destroying the conserved 
residues (figure 1).  In using this alignment-based approach, we aspired to create three segments 
from both human TRMT10A and TRMT10B followed by the splicing of segments from the 
different proteins to create new chimeric proteins composed of both TRMT10A and TRMT10B 
sequences.  We named these new chimeric proteins by correlating the segments of each hybrid to 
their protein of origin using the letters A and B.  For example, the BAA hybrid protein would be 
composed of the N-terminus fragment from the TRMT10B protein, the SPOUT core from 
TRMT10A, and the C-terminus fragment from TRMT10B.  In total, six chimeric proteins were 
formed; three with TRMT10A cores, and three with TRMT10B cores (translated from assembled 
chimera in figure 2). In doing this, we sought to elucidate whether there was any effect that the 
N-terminal and C-terminal sequences held on the SPOUT core activity.  Does there exist any 
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residues within the terminal domains that interfere with or promote catalysis?  If so, are we able 
to determine if these exist within the N-terminal or C-terminal domain?  The synthesis of these 
chimeric proteins was the first step to answering these questions in this thesis, and this was 
followed by the purification of the proteins and the subsequent testing for m1G9 and m
1A9 
activity using radioactive enzymatic activity assays (using substrates tRNAAsp to test m1A9 
activity, and tRNAtrp to test m1G9 activity).  It was hypothesized that the protein’s activity would 
be solely determined by whether a TRMT10A or a TRMT10B SPOUT core was present within 













8 | P a g e  
 
Chapter 1: Cloning TRMT10A and TRMT10B Constructs to Generate Chimeric Proteins 
 
To synthesize the TRMT10A and B chimeras, DNA synthesis for each fragment was 
required.  Upon completing the analysis of wild type Trm10 amino acid sequences across 
multiple species, and determining conserved amino acids, break points in the wild type 
sequences were determined such that none of the conserved residues in the SPOUT catalytic core 
would be compromised by removal and replacement of the appended N- and C-terminal 
domains.  This ensures that if these conserved residues hold catalytic function, this would not be 
destroyed in creating the chimeric proteins.  Along with this, we decided to add an arbitrary 
sequence to the end of the C-terminal TRMT10B fragment, as this fragment based on the 
alignment and conserved residues was exceptionally short.  This ensured that there was no loss 
of sequence during the assembly of the completed DNA vector later in the experiment.  In total, 
five fragments of TRMT10A and five of TRMT10B were designed (figure 2).  The five-
fragment strategy was chosen to make it easier to assemble the gene for the complete chimeric 
protein from two fragments rather than to have to ligate each of the three domains (N-terminus, 
SPOUT core and C-terminus) independently. For example, to create the chimeric protein that is 
composed of an N-terminus TRMT10 A, a TRMT10A SPOUT core, and a TRMT10B C-
terminus, we designed primers to amplify the two TRMT10A sections together as one fragment, 
while amplifying the TRMT10B C-terminus separately.  Using the wild-type constructs for each 
protein as a template, primers for each fragment were designed, purchased, and used in 
conjunction with polymerase chain reaction (PCR) to synthesize these DNA fragments.  
An agarose gel electrophoresis was performed to determine whether the size of the 
amplified fragments reflected the expected size.  After confirming proper synthesis of the 
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individual fragments, the bands that matched the expected size were cut out to avoid 
contamination and unwanted sequences from being present in the assembly reactions.  A gel 
extraction and PCR clean-up was performed to obtain the DNA fragment in solution and to 
minimize contaminants in the sample. Concentrations of each fragment were measured using a 
nanodrop instrument to ensure that sufficient amounts of each fragment were used in the 
assembly steps to follow.  The fragments were then recombined and spliced together using 
Gibson assembly such that all possible hybrid sequences were formed.  This type of assembly 
allows for precise “sticky ends” of certain length to be created on the double stranded DNA 
fragments using an exonuclease such that the single strand portion is complementary to that of 
another fragment with which it will be assembled to. Each of the five fragments were designed to 
generate appropriate sequences for assembly when performing the alignments of the wild type 
sequences in the first step. To ensure that the chimera sequences were assembled correctly and 
were ligated to the vector, the assembled reactions were then transformed into Escherichia coli 
cells and plated on LB plates containing ampicillin. This ensures that the only colonies that grow 
when incubated overnight are the ones that have the vector of focus, as the vector used in these 
experiments is designed to be resistant to ampicillin, conferring resistance into the E. coli within 
which it is transformed.  With that being said, there still could be vectors transformed that do not 
contain the assembly, so minipreps were created for multiple colonies of each assembly.  
Agarose gels were then run for these minipreps following a restriction digest with specific 
restriction enzymes for the assemblies. This was used to visualize whether the properly 
assembled vector was created, because if it was the vector would be digested into appropriately 
sized bands on the agarose gel.  To confirm this result, the samples that showed the expected 
patterns of digestion were sent for sequencing.  
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Results 
Fragment Synthesis: The PCR performed to synthesize the fragments needed for this assembly 
appeared largely successful, with the initial round of fragment synthesis resulting in good yield 
for 9 out of the 10 fragments designed (figure 3).  The sole exception to this was the fragment 
composed of the SPOUT core of TRMT10A and the C-terminus of TRMT10A (Fragment 
A2A3).  This fragment was barely observable on the 1% agarose gel (figure 3, top gel), and the 
yield was so low that it was determined to be best to go through the PCR process once again with 
it.  While doing this, we chose to perform a PCR screen testing alternative temperatures of 
annealing, substitution of buffers (using GC buffer designed for sequences with high guanine and 
cytosine content), and the inclusion of DMSO into the solution.  Upon completing this PCR 
screen, the high temperature PCR procedure using the original mix for the PCR was found to 
yield the best results for the missing TRMT10A fragment (A2A3), so this sample was used 
moving forward.  With the completion of this screen, we were able to obtain all of the fragments 
needed for the next steps. 
Purification, Sequencing, and Quantification: The 10 fragments that appeared to be of the 
correct size were sequenced to confirm that they were correct. From there, each fragment was 
further purified using gel extraction and PCR clean up to remove contaminants before 
determining their concentrations using UV absorbance measured on a nanodrop instrument. Most 
fragment concentrations ranged from 0.05-0.07 μg/μL (figure 4).  The two exceptions to this 
were the N-terminus and SPOUT core TRMT10B combined fragment (B1B2) and the C-
terminus TRMT10B fragment (B3), which had concentrations of 0.0131 and 0.0146 μg/μL, 
respectively, which was somewhat low but judged to be still good enough to move forward with 
the next steps of the cloning process.  Notably, due to the small size of the C-terminus 
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TRMT10B fragment (B3), the molar concentration of this fragment is correspondingly higher 
than it seems based on the mass concentration (μg/μL) and therefore was sufficient for assembly.  
Along with the concentrations obtained via nanodrop, the ratio of the absorbance values at 260 
nm and at 280 nm were obtained for each of the fragments.  This ratio allows for the purity of the 
DNA fragment to be assessed, as a pure sample of double-stranded DNA would be expected to 
exhibit a 260/280 value close to 1.80.  For the most part, this was observed for each of the 
fragments, with the largest discrepancy being the N-terminal TRMT10B fragment at 1.50 (B1). 
Gibson Assembly: With fragments assembled and their respective sequences confirmed, we 
were able to proceed with the Gibson Assembly of each chimeric sequence and into a prepared 
vector.  When preparing the vector for assembly, it was important to linearize the DNA using a 
restriction enzyme so that the assembled gene sequence could be inserted into the vector.  The 
prepared vector was digested and purified according to the procedure in the methods, yielding a 
final concentration of 0.0087 μg/μL with a 260/280 value of 1.80, so this vector was used for the 
assembly.   
Using the concentrations for each amplified fragment obtained previously, it was 
important to ensure there was a specific mass of each fragment and vector added into the reaction 
mix. The first sequences to be assembled and transformed into cells to be plated onto LB+amp 
plates were the BAA, BBA, and AAB sequences (B1+A2A3, B1B2+A3, and A1A2+B3, 
respectively).  It was observed that these transformations had rather low yields, with only a few 
colonies grown per plate.  Nevertheless, two of each of these colonies were grown in liquid 
cultures for minipreps, which were eventually run on a 1% agarose gel upon being cut by the 
restriction enzymes PvuII (to indicate the presence of the TRMT10A core) and ClaI (to indicate 
the presence of the TRMT10B core).  Subsequent assembly reactions with the other fragments 
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yielded many more colonies that were tested by restriction digest in the same way.  Upon 
running all of the digested sequences on an agarose gel, it was determined that a successful 
vector assembly was obtained during the first round of assembly for the BAA, ABB, and BBA 
sequences, as these exhibited the correct digestion patterns on the gels.  To ensure that this was 
the case, they were sent for sequencing which further confirmed these results.  Generating the 
remaining constructs required additional colony screening and in two cases (AAB and BAB), 
also required additional assembly reactions to be carried out.  After sequencing confirmed these 
results, expression constructs for all six protein chimera have been successfully created and we 












13 | P a g e  
 
Chapter 2: Expression and Purification of Chimeric TRMT10A/TRMT10B Proteins 
Upon obtaining the correctly assembled vectors for each of the chimeric TRMT10A/B 
sequences, the next step taken was to transform the DNA vector into BL-21 competent cells in 
preparation of growing cultures for these constructs.  The BL-21 cells were utile in this situation 
due to the fact that these competent cells are exceptional for protein synthesis, and typically have 
a good protein yield when synthesizing proteins (Donahue and Bebee, 1999).  Upon 
transforming the vector into these cells on an LB+Amp plate, 5 mL cultures were grown from 
the resulting colonies after incubation.  The reason behind growing 5 mL cultures first lies in the 
fact that it is much easier to transfer a colony into a culture of small volume.  From there, the 5 
mL culture was sequentially transferred into a 25 mL culture and then to a 1 L culture upon 
visible growth.  Throughout each of these steps, it was important to ensure that sufficient 
ampicillin was present in solution such that all other contaminating species that do not contain 
the ampicillin resistance that our vector provides would be killed off.  To ensure sufficient and 
consistent growth across all cultures, the general protocol followed was to grow the 5 mL culture 
over the span of a day at 37⁰C, then to grow the 25 mL culture (resulting from the transfer of the 
entire 5 mL of the previous culture) overnight at 37⁰C before transferring sufficient volume of 
this culture into the 1 L culture such that the starting optical density (OD) taken at 600 nm is at 
0.05.  This allows for the growth time of this culture to be more predictable, as the doubling time 
for these cells is roughly 60 minutes, and the target optical density to achieve for induction with 
Isopropyl β-d-1-thiogalactopyranoside (IPTG) is OD600~0.4-0.6.   
Upon reaching the target OD600, a sample of cells was taken and stored at -80⁰C to use as 
a sample representing the proteins present prior to IPTG induction of the protein chimera (figure 
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5).  From there, 1 mL of 1M IPTG was added to the culture and allowed to grow for 6 hours.  
These cultures were then able to be spun down, flash frozen using dry ice, and stored at -80⁰C.   
The next step was to purify the proteins that were obtained using metal affinity 
chromatography with TALON beads.  The cobalt in the TALON beads binds to the 6-His tag 
engineered into the chimera proteins, allowing the remaining proteins synthesized during the 
process of culture growth to be eluted and removed throughout the multistep process of 
purification, ideally yielding the pure target protein.  An important step in this process is the 
French Pressing of the cells such that they are lysed and the proteins are no longer held behind a 
plasma membrane, generating a crude soluble lysate.  Upon completion of the washes that follow 
this stage and sequentially loading of the lysate onto the column, the protein was eluted off of the 
TALON beads by adding Imidazole.  A high concentration of this molecule competes with the 6-
His tag to bind with the TALON beads, effectively removing the protein from them. The eluted 
fractions were collected in multiple microcentrifuge tubes, and a 10 μL portion of each fraction 
was tested via Bradford Assay to determine the protein-containing fraction(s) by their blue color.  
This allowed me to determine which fractions contained the most concentrated proteins, and 
these fractions were pooled for further dialysis, where they would be concentrated and 
exchanged into an appropriate buffer for long-term storage.  Our goal in this process is to get the 
most concentrated, pure protein, and all the steps discussed work towards this goal.   
To analyze the results of this purification process, an SDS-PAGE experiment was run for 
each purified protein, analyzing the pure protein along with the washes performed during 
purification, the crude extract resulting from the lysis of the E. coli cells, the flow through 
(resulting solution after the introduction of TALON beads into the crude extract to bind the 
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target protein), and a ladder for size scaling (figure 5).  This visualization allowed us to check the 
relative purity of the protein and to determine whether the protein is of the correct size. 
 
Results  
Upon completing this process for all six chimeric proteins, four (AAB, BAA, ABA, and 
BBA) were purified in relatively high yield and could be used directly in activity assays (see 
chapter 3).  The BAB protein and the ABB protein did not appear to purify well the first time, as 
there was no clear and concise band present in the dialyzed fraction at the size expected for these 
proteins (see figure 5).  Lack of pure ABB protein might be attributed to human error, as during 
this purification, the imidazole elution buffer, which removes the protein from the TALON 
beads, was added prematurely, and the protein was collected before the final wash and column 
elution procedure could be carried out (and thus required additional concentration).   
Because the BAB protein was of the greatest concern, as we were not aware of any errors 
that occurred during its preparation, this protein was tended to first to determine optimal 
bacterial expression conditions for it.   
The goal in running a test expression is to determine what conditions best suit the 
translation of the chimeric proteins we are interested in in the bacterial cells.  In running this test 
expression the temperature at which the cells grow was tested along with the type of competent 
cells used, and the amount of IPTG used to induce target protein formation.  All possible 
combinations of these conditions were studied, and upon being sonicated to induce the lysis of 
the cell, extracts corresponding to each condition were analyzed using SDS-PAGE (figure 6).  
The results between the ABA and the BAB proteins were consistent, as both SDS-PAGE gels 
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displayed that the use of Rosetta-pLysS cells at a growth temperature of 18⁰C and 0.1 M IPTG 
were most beneficial for expression of both proteins.  The only issue that arose regarded the 
BAB protein, as it was not the proper size according to the standards, which was noted, but it 
was still decided that these conditions would also be best for the other chimeric proteins.  The 
rationale behind this decision is the fact that these proteins are translated from many similar 
mRNA sequences that are shared between multiple chimera, and therefore it was reasonable to 
assume that these expression conditions would apply to the rest of the chimera.  
Unfortunately, when expressing and purifying the ABB chimeric protein using these 
optimized conditions, another issue arose, as it also appeared that the expressed protein was 
about 10 kD larger in size than expected according to the standards on the SDS-PAGE.  At this 
point, it was decided to send the BAB miniprep in for sequencing to determine if this was a 
problem with the construct sequence.  It was decided that sending the BAB fragment for 
sequencing would provide sufficient information regarding this issue, as both the BAB and ABB 
chimera displayed the same problem, allowing the assumption to be made that they were affected 
by the same issue.  The results displayed the correct sequence, showing that this was not the 
issue.  The isoelectric points of the proteins were also looked at, as a protein with a high 
isoelectric point may run aberrantly on an SDS gel.  This was also not the issue, as both of the 
proteins experiencing issues had isoelectric points around 8-9, which is not outside of a typical 
range.  At this point, its was assumed that we indeed had the right protein, but some unknown 
factor was affecting its ability to be resolved correctly on an SDS-PAGE experiment.  Thus, at 
this point we had obtained all six of our chimeric proteins, although some questions remain about 
the status of the BAB and ABB proteins. The purified protein samples varied in concentration 
slightly, and ranged from less than 1 mg/mL to over 4 mg/mL in total concentration.  Knowing 
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these concentrations will be important moving forward, as in order to perform activity assays, a 
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Chapter 3: Activity Assays 
 For the final stage of this thesis, I used enzyme activity assays to determine whether the 
chimeric proteins synthesized in previous stages display m1G9 or m
1A9 activity.  In this process, 
we used alpha-ATP to uniformly label in vitro transcribed tRNAAsp, as this tRNA has an adenine 
present at the ninth position (A9), and is a known substrate for human TRMT10B.  On the other 
hand, we use alpha-GTP to uniformly label an in vitro transcript of tRNATrp to test for m1G9 
activity, which is a known activity of humanTRMT10A.  Uniform labeling is a process by which 
a tRNA is synthesized with three normal nucleotides and one radioactively labeled nucleotide, 
such that each position in the tRNA that corresponds to the labeled nucleotide is now replaced 
with the radioactive alternative.  This labeling reaction is performed by T7 RNA polymerase 
using DNA templates that were created by a previous graduate student in the laboratory (Dr. 
Nathan Howell).  This radiolabeled tRNA is useful in future procedures, as it facilitates imaging 
of the methylation activity of the chimera using thin layer chromatography (TLC), after a 
procedure described in more detail below.  Imaging of each reaction will enable visualization of 
a radioactive spot on the TLC plate corresponding to the methylated nucleotide in the tRNA, 
which is separated from the unmethylated nucleotide because of its different mobility in the 
mobile phase of the chromatographic solvent.  
 Enzyme activity reactions were run in the presence of each chimeric enzyme and the 
labeled tRNA at 30⁰C.  Each enzyme was tested in three reactions, where the reaction was 
performed in subsequent ten-fold dilutions of enzyme concentration (undiluted, 1:10 dilution, 
1:100 dilution).  This allows for the visualization of the dependence of activity on the  
concentration of enzyme in each assay.  It also allows for the inference of relative reaction rates, 
as an enzyme reacting at a high rate would still present a spot on a TLC plate, even if it is present 
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at a low concentration (while a less active enzyme might not generate a product spot at the 
lowest concentrations).  The concentration of substrate tRNA added in each reaction was 
determined using the scintillation counter to measure the total radioactivity in the labeled 
preparation, and was approximately 3000 cpm/reaction.  
Along with the chimeric proteins, this reaction was also performed with positive and 
negative controls to ensure the validity of the results.  For m1G9 activity assays, both yeast 
Trm10 and WT human TRMT10A were used as positive controls, as they both are known to 
perform m1G9.  For m
1A9 assays, TkTrm10 was used as a positive control, as this enzyme has 
been shown to perform m1A9 (Singh et. Al., 2018, Krishnamohan et. Al, 2019).  The negative 
control used was a reaction where no enzyme was present. These reactions were buffered and 
were performed in the presence of S-adenosyl methionine (SAM), as this acts as the methyl 
donor for the enzymes to act upon the substrate.  Without SAM, the reactions would not be able 
to proceed.  After one hour of reaction, the reactions were stopped by the addition of a large 
amount of a large amount of unlabeled yeast tRNA and a solution of phenol:chloroform, which 
completely denatures the protein and allows the RNA to be separated from the other reaction 
components. Then, a P1 nuclease was used to digest the tRNA into individual nucleotides, where 
they were visualized on a TLC plate.  Without digestion, the tRNAs would run as a single spot 
on the TLC, making it impossible to determine whether methylation occurred or not. 
 
Results 
 Upon completion of this process and the subsequent development of the TLC plates, 
imaging was performed, and these images were subsequently labeled and analyzed (figure 7).  
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All positive controls for both types of activity showed the appropriate patterns of methylation.  In 
addition, the BAA and AAB constructs displayed m1G9 activity which tapered off in 
correspondence with the dilutions.  It is important to note that the BAB construct did not perform 
m1G9, despite being expected to do so based on the results with BAA and AAB chimera.  This 
expectation stemmed from the fact that this chimera still contains the TRMT10A SPOUT core, 
which typically would perform m1G9.  There are several possible explanations for this 
phenomenon.  First, this could occur due to the misfolding of the BAB protein causing inactivity 
in the protein, which did not occur when only one of the terminal domains was replaced.  
Another possibility could be the lack of robust expression that was observed in the BAB protein, 
which led to low purification yields and thus difficulty detecting activity.  An exciting possibility 
lies in the idea that the C-terminal and N-terminal domains play a role in the enzymes activity, 
and in the situation when both of the domains have been replaced by sequences from TRMT10B, 
which are not normally associated with the SPOUT core, it is unable to perform it’s activity. The 
determination as to which of these options is correct was unable to be made due to a lack of time 
for me to carry out more experiments, but is planned to be studied following the completion of 
this thesis.  
From an m1A9 standpoint, there was no apparent activity in any of the tested chimera.  
Again, there are multiple factors that could contribute to this phenomenon.  These factors mirror 
those which contributed to the issues with the BAB protein with regards to m1G9 activity.  Along 
with those previously discussed, there is a possibility that the chimeras performed m1A9 activity 
at a much lower rate than that of TkTrm10, such that they were not visible on the assay 
conducted.  Regardless, this assay suggests that the chimeras are affected by the alterations of the 
appended domains on the protein’s SPOUT core.  Moving forward, the chimera proteins will be 
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assayed at a higher concentration to determine if any activity can be detected under these 
conditions.  Again, it is important to note that this assay was performed before the test 
expressions discussed previously, so the new protein purification resulting from the test 
expressions may alter the outcome of the assays in the future. 
Overall, these assays show that the activity of the TRMT10A SPOUT domain is not fully 
dependent on having both C- and N-terminal TRMT10A domains appended to the SPOUT core.  
Initial data suggests that there does exist some level of dependence on having at least one of 
these fragments be TRMT10A, as the BAB construct does not show methylation.  On the other 
hand, the complete loss of m1A9 activity for any of the tested chimera proteins suggests that there 
is some level of dependence on having TRMT10B C- and N-terminal fragments in the protein 
for catalytic activity.  These are only preliminary results and are subject to change with future 
studies, but they give great insight into the importance of these appended domains on either side 
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Materials and Methods 
PCR synthesis of fragments: Forward and reverse primers (2.5 μL of 10 μM concentration), 
template DNA (1 μL), dNTPs (1 μL of 10 μM concentration), 5x iProof buffer (10 μL), and 
iProof DNA polymerase (0.8 μL) were mixed in water (32.2 μL) to create a 50 μL solution 
before placing it in the thermal cycler to start the PCR process.  It was ensured that no bubbles 
existed in the solution, and that all of the sample was at the bottom of the tube by spinning the 
sample before thermal cycling.  The protocol for the thermal cycler can be broken down into four 
stages and was as follows: first stage: 98⁰C for 1 min.  Second stage:  98⁰C for 30 s followed by 
37⁰C for 1 min and then 72⁰C for 1 min (this cycle was repeated five times).  Third stage: 98⁰C 
for 30 s then 42⁰C for 1 min followed by 72⁰C for 1 min (this stage was repeated 25 times).  
Fourth stage: 72⁰C for 10 min and then held at that temperature until removal from thermal 
cycler. 
Vector Assembly: Using the gel purified and linearized vector resulting from digestion with 
NruI and PmeI (0.05 pmols used per reaction), the assembly solution was made along with the 
fragments needing to be assembled at a 1:10 dilution (such that 0.05 pmols of each fragment 
were introduced), and 10 μL of HiFi DNA master mix.  These materials were placed in 10-x μL 
of water, where x corresponds to the total volume of fragments and vector in the solution.  This 
was then incubated at 50⁰C for 15 min, followed by transformation onto an LB+Amp plate.  In 
this transformation, 2 μL of the previous reaction was mixed with 50 μL of NEB-5-α competent 
E. coli cells before plating the entire volume and incubating overnight at 37⁰C. 
Protein Prep: Protein preps for the chimeras were obtained using two protocols.  The first used 
consisted of performing a transformation of the chimeric sequence of focus using BL-21 
competent cells such that 50 μL of competent cells were mixed with 2 μL of the DNA.  This 
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solution was iced for 30 min before being heat shocked at 50⁰C for 45 s.  Following this, the 
solution was iced for an additional 2 min before mixing with 300 μL of LB and plating 50 μL on 
an LB+amp plate to be incubated overnight at 37⁰C.  From there, colonies were selected and 
grown in 5 mL LB cultures with 5 μL of Ampicillin added.  These were grown throughout a day 
before being transferred to 25 mL LB cultures with 25 μL of Ampicillin in the evening.  These 
were grown overnight before the proper volume was transferred to a 1 L culture with 1 mL of 
ampicillin such that the starting OD600 was set at 0.05.  This was grown until reaching an OD600 
of roughly 0.5 before being induced with 1 mL of 1 mM IPTG and grown over the remainder of 
the day.  All growth took place at 37⁰C.  These cultures were then spun down to form a pellet 
before being resuspended and transferred to two 50 mL conical vials.  These vials were also spun 
for pelleting and flash frozen with dry ice before storing at -80⁰C.  The protocol differed 
following the test expressions performed, as multiple stages were changed.  Firstly, the 
competent cells used in the transformation changed to Rosetta-Plyss.  The remaining 
transformation protocol stayed consistent.  The next difference stemmed from the concentration 
of IPTG used for induction, as this changed to 1 mL of 0.1 mM IPTG.  The last change made 
was the temperature of growth after induction to 18⁰C.  All other temperatures were consistent, 
but this alteration resulted in growing the liter culture overnight before spinning it down.   
SDS-PAGE:  To start, the SDS resolving gel was made, with 2.5 mL of 40% Acrylamide, 2.5 
mL of 1.5 M Tris pH 8.8, 0.1 mL of 10% SDS, 4.85 mL of water, 0.1 mL of 10% APS, and 0.01 
mL of TEMED.  This was poured into the plates and allowed to polymerize.  Then, the stacking 
gel was made with 0.5 mL of 40% Acrylamide, 0.62 mL of 1 M Tris pH 6.8, 0.05 mL of 10% 
SDS, 3.82 mL of water, 0.025 mL of APS, and 0.005 mL of TEMED.  This was poured to the 
top of the plates and allowed to polymerize with a comb in it.  The samples were then prepared 
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to be run using 10 uL of SDS running dye and 2 uL of each sample.  These mixtures were then 
heated at 95⁰C for 10 min.  They were then loaded into the gels and run at 130 V until the bands 
were close to the bottom of the gel.   
 Upon completion of the gel, it was stained with Coomassie blue stain over one hour 
before using destain on it.  These gels were then imaged over a light source and analzyed. 
Activity Assay:  First, a common mix was made for all of the reactions.  When broken down to 
the volume per reaction, this mix contained 0.5 μL of 1000 mM Tris pH 8, 0.15 μL of 100 mM 
MgCl2, and 0.25 μL of 20 mM SAM.  The substate tRNA volume added into the common mix is 
dependent on the concentration of the hot tRNA, which is determined through the use of the 
scintillation counter.  Lastly, water is added so that the total volume of the mix for each reaction 
is 9 μL.  This volume is then mixed with 1 μL of an enzyme.  It is important to dilute the 
concentrations of the enzymes such that their concentrations match the least concentrated 
chimera.  They are diluted using a dilution buffer stock composed of 20 μL of 1 M Tris pH 7.5, 
10 μL of 50 mg/mL BSA, 1 μL of DTT, and 969 μL of water. Upon mixing the common mix 
with the enzyme, the reaction is set at 30⁰C for one hour.  Upon completion of this, stop 
reactions are introduced to stop the process of methylation.  The mix for these stop reactions 
consists of 2 μL of yeast tRNA (10 mg/mL), 50 μL of 1 M Tris pH 8, and 38 μL of water.  These 
volumes are for each reaction, such that 90 μL were added to the 10 μL reactions performed 
previously.  A PCA clean-up was then performed using PLG tubes.  The samples were placed in 
the PLG tubes before being shaken, spun down for 5 minutes, and removing the aqueous top 
layer to be placed in a new microcentrifuge tube.  200 μL of 100% ethanol was then added 
before placing them at -20⁰C for 30 min.  The tubes were then spun at 4⁰C for 15 min before 
removing the 100% ethanol (ensuring that the pellet formed is not disturbed).  200 μL of 70% 
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ethanol was then added as a wash, where it was then spun down once again at 4⁰C for 15 min.  
Once all ethanol was removed, the P1 digest mix was added.  This consisted of 2.6 μL of 50 mM 
NaOAc (pH 5.2), 0.4 μL of 2 mM ZnCl2, and 1 μL of 1 mg/mL P1 nuclease.  These volumes are 
per reaction.  The tRNA in solution was then digested at 50⁰C for one hour before spotting 2 μL 
on a TLC plate and developing in a tank overnight.  These results were then able to be imaged 
































Figure 1: Sequence alignment. Conserved and potentially important sequences of Trm10 across multiple 
species. Include Human TRMT10A, B, and C, S. cerevisiae Trm10, S. Acidocaldarius Trm10, and S. Pombe 
Trm10. 















Figure 2: Chimeric Sequences of TRMT10.  The wild type TRMT10A and B DNA was fragmented and 
spliced together to yield six different chimera DNA sequences (above). Fragments made to assemble these 
sequences seen at bottom.  Adapted from figure made by Dr. Nathan Howell. 
   (m1A9) 
       A1                                                A2                                                    A3 
       B1                                                B2                                                    B3 


























Figure 3: Agarose gels for TRMT10A/B fragments.  Display of the fragments and their 
respective sizes.  Lane 5 in the first gel displays the only low product yield, which was 
corrected in later stages with a PCR screen. 





























Fragment Identity Concentration 
(ug/uL) 
260/280 
A1 0.0481 1.85 
A2 0.0642 1.86 
A3 0.0660 1.84 
A1A2 0.0131 1.85 
A2A3 0.0653 1.80 
B1 0.0925 1.50 
B2 0.0937 1.84 
B3 0.0146 1.87 
B1B2 0.0780 1.84 
B2B3 0.0657 1.90 
Vector 0.0087 1.80 
Figure 4: TRM10 Fragment and Vector Concentrations.  Determined using nanodrop.  
Important for Gibson assembly.  260/280 value gives insight into purity of sample. 




Figure 5: SDS-PAGE Analysis of Protein Expression.  Gels run for each protein made.  
Lane identity displayed for each case. 
          






Figure 6A: BAB Expression Tests.  Expression tests performed on the BAB construct altering temperature, 









               
                           
       
               
       
                
                 
       
                  
    
                 
       
                  
               
       
                 







Figure 6B: ABA Expression Tests. Expression tests performed on the ABA construct altering temperature, 
































Figure 7A: m1G9 assays.  Assays performed using chimeric enzymes and Trp tRNA.  Images 
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Figure 7B: m1A9 assays.  Images show a lack of methylation for all protein chimeras, but the 
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